LENZ
LENZ Therapeutics Inc.

1,266
Mkt Cap
$377.04M
Volume
659,023.00
52W High
$50.40
52W Low
$11.83
PE Ratio
-5.72
LENZ Fundamentals
Price
$11.59
Prev Close
$12.05
Open
$11.93
50D MA
$17.16
Beta
1.41
Avg. Volume
1.24M
EPS (Annual)
-$2.34
P/B
1.78
Rev/Employee
$0.00
$406.62
Loading...
Loading...
News
all
press releases
LENZ Therapeutics, Inc. $LENZ Shares Acquired by Skandinaviska Enskilda Banken AB publ
Skandinaviska Enskilda Banken AB publ lifted its stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 99.0% in the 3rd quarter, according to its most recent Form 13F filing with...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Short Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Decreases By 16.8%
LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) was the target of a significant decrease in short interest in the month of January. As of January 30th, there was short interest totaling...
MarketBeat·4d ago
News Placeholder
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Moderate Buy" by Brokerages
Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the firm...
MarketBeat·15d ago
News Placeholder
New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug
FDA approved Tenpoint's Yuvezzi eye drop for presbyopia, adding competition for LENZ's VIZZ as analysts say the recent stock drop may be overdone and see blockbuster potential ahead.read more...
Benzinga·21d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ...
PR Newswire·29d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ...
PR Newswire·1mo ago
News Placeholder
LENZ Therapeutics (NASDAQ:LENZ) Trading Up 9.5% - Should You Buy?
LENZ Therapeutics (NASDAQ:LENZ) Trading 9.5% Higher - What's Next...
MarketBeat·1mo ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ...
PR Newswire·1mo ago
News Placeholder
LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year Low - What's Next?
LENZ Therapeutics (NASDAQ:LENZ) Hits New 12-Month Low - What's Next...
MarketBeat·2mo ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ...
PR Newswire·2mo ago
<
1
2
...
>

Latest LENZ News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.